Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of inhaled human insulin powder versus intensified insulin glargine in adults with type 2 diabetes
2006-000247-26Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of human insulin and insulin glargine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to 6 months. Started Mar 2006; status: terminated.
02
Drugs
human insulininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-000247-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000247-26.